Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home
  
Scientific News
New Treatment for Pancreatic Cancer
Researchers at Purdue University have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
How Different People Respond To Aspirin
Study findings could be used to help identify those who would benefit most from aspirin use.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
A Metabolic Twist that Drives Cancer Survival
A novel metabolic pathway that helps cancer cells thrive in conditions that are lethal to normal cells has been identified.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Living Off the Fat of the Land
Do cancer cells synthesize the parts for new cells or scavenge them from the environment?
Liver Disease, Obesity Linked
Kanazawa University researchers find similarities in the impeded signalling between central insulin activity and glucose production in the liver for both obese mice and mice that have had the vagus nerve removed.
Decoding Ties Between Vascular Disease, Alzheimer’s
NIH consortium uses big data, team science to uncover complex interplay of factors.
Gene Identified that May Worsen Cancer Outcome
Some patients with breast cancer, lung cancer and leukaemia seem to fare poorly after treatment because of the effects of a particular gene, a new study finds.

Multiplexed Diagnostics 2010
Bookmark and Share

Published: May 2010
Pages: 572
Published by: BioPerspectives

The multiplexed diagnostics market has grown rapidly and generated sales of approximately $2.4 billon in 2009, but is now balanced on multiple tipping points. Will the FDA finally release the updated IVDMIA guidelines? If so, will the FDA close the CLIA loophole and/or will the FDA require 510(k) approvals for all multivariate diagnostics? Will Genomic Health and Agendia be able to maintain high prices for their flagship tests amidst growing competition? How many new tests will reach the market in 2010? Does the inability of Genomic Health’s new colon cancer diagnostic to predict response to chemotherapy indicate ongoing challenges in developing new multivariate diagnostics or is this an isolated example? Will growing competition lead to market confusion? In situations with similar tests, how will physicians and payers decide? Will they want to see more prospective clinical trials? Will prospective clinical trials be more attractive due to the experience of XDx? As multiplexed diagnostics become more established, will physicians and payers begin to actively seek these new tests to increase the efficiency of healthcare? Will changes in healthcare policies, especially in the US, be a net positive because of the expanded use of tests (for aging and expanding populations) or a net negative because of cost controls? Will new multiplexing technologies, such as MagPix from Luminex and BeadXpress from Illumina, create another shift in the market or are diagnostics laboratories becoming entrenched with current methods? Will new biomarkers, such as microRNA and methylated DNA, be more powerful than gene expression levels? For genetic tests, how far will multiplexing go? Is Counsyl’s combination of 100 genetic tests only the beginning? If so, will the increasing complexity of genetic tests usher in the era of diagnostic DNA sequencing?

On the whole, the multiplexed diagnostics market is expected to tip in favor of continued rapid growth, reaching almost $5.8 billion in 2015, according to a new report, Multiplexed Diagnostics 2010, published by Select Biosciences and written by BioPerspectives and Bachmann Consulting. This report explains the unmet needs, trends, regulations, reimbursement, competition, technologies and business strategies. This 572-page report includes a survey of more than 400 respondents, interviews with 12 experts, a detailed database of more than 190 commercial multiplexed diagnostics and a two-tiered quantitative worldwide market model. In addition, the report comes with one hour of consulting (in the form of a conference call) with one of the authors, Dr. Steven Bodovitz, Principal of BioPerspectives, or Dr. Jutta Bachmann, CEO of Bachmann Consulting.


Related Content

Technology Networks Presents Poster Award at Advances in Metabolic Profiling Conference
The publishers of Metabolomics.net sponsored the poster award at Select Biosciences 2nd annual AMP conference.
Monday, October 30, 2006
Call for Papers - European Biomarkers Summit
Experts from both academia and commerce are invited to present timely information from current research through to commercial implementation of new technologies.
Thursday, February 09, 2006
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!